‌

US Patent 8476409 Bispecific anti-IGF-1R and anti-ErbB3 antibodies

Patent 8476409 was granted and assigned to Merrimack Pharmaceuticals on July, 2013 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Merrimack Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8476409

Patent Inventor Names

Jason Baum0

Lihui Xu0

Jonathan Basil Fitzgerald0

Sharlene Adams0

Neeraj Kohli0

Alexey Alexandrovich Lugovskoy0

Bryan Johnson0

Date of Patent

July 2, 2013

Patent Application Number

13451135

Date Filed

April 19, 2012

Patent Primary Examiner

‌

Sheela J. Huff

Patent abstract

Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8476409 Bispecific anti-IGF-1R and anti-ErbB3 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API